Paratek Pharmaceuticals Inc
F:N4CN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
J
|
Johor Plantations Group Bhd
KLSE:JPG
|
MY |
Paratek Pharmaceuticals Inc
Accounts Receivables
Paratek Pharmaceuticals Inc
Accounts Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
P
|
Paratek Pharmaceuticals Inc
F:N4CN
|
Accounts Receivables
$42.3m
|
CAGR 3-Years
54%
|
CAGR 5-Years
116%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Accounts Receivables
$17.2B
|
CAGR 3-Years
2%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Accounts Receivables
$9.8B
|
CAGR 3-Years
4%
|
CAGR 5-Years
6%
|
CAGR 10-Years
13%
|
|
|
Pfizer Inc
NYSE:PFE
|
Accounts Receivables
$11.9B
|
CAGR 3-Years
3%
|
CAGR 5-Years
8%
|
CAGR 10-Years
4%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Accounts Receivables
$11.8B
|
CAGR 3-Years
8%
|
CAGR 5-Years
8%
|
CAGR 10-Years
6%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Accounts Receivables
$17.8B
|
CAGR 3-Years
37%
|
CAGR 5-Years
25%
|
CAGR 10-Years
18%
|
|
Paratek Pharmaceuticals Inc
Glance View
Paratek Pharmaceuticals, Inc. engages in the development and commercialization of therapies based upon tetracycline chemistry. The company is headquartered in Boston, Massachusetts and currently employs 207 full-time employees. The company went IPO on 2006-05-10. The firm is focused on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use. The firm's lead product, NUZYRA (omadacycline), is an oral and intravenous antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia (CABP), and acute skin and skin structure infections (ABSSSI), caused by susceptible pathogens. Omadacycline is used in the emergency room, hospital, and community care settings. Its second product, SEYSARA (Sarecycline), is an oral therapy for the treatment of moderate to severe acne vulgaris.
See Also
What is Paratek Pharmaceuticals Inc's Accounts Receivables?
Accounts Receivables
42.3m
USD
Based on the financial report for Jun 30, 2023, Paratek Pharmaceuticals Inc's Accounts Receivables amounts to 42.3m USD.
What is Paratek Pharmaceuticals Inc's Accounts Receivables growth rate?
Accounts Receivables CAGR 5Y
116%
Over the last year, the Accounts Receivables growth was 33%. The average annual Accounts Receivables growth rates for Paratek Pharmaceuticals Inc have been 54% over the past three years , 116% over the past five years .
